Heart failure & cardiomyopathies
Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry
Authors' conclusion
Real-world data from the ELEVATE registry demonstrate an overall survival rate for primary implants of 63.3%.
Study context
- Population
- Patients implanted with the HeartMate 3 (HM3) LV assist device at 26 centres, March 2015–February 2017
- Participants
- 540 patients · 26 centres
- Exposure
- PIC vs Pump exchange vs AC
- PICn = 463
- Pump exchangen = 19
- ACn = 58
Methodological detailsmulticentre, real-world, post-CE Mark
- Multicentre
- Real-world
- post-CE Mark
Main finding
As reported in the abstract
Overall survival and survival free of stroke (PIC) · 5 years
| Group | Overall survival | Survival free of stroke |
|---|---|---|
| PIC | 63.3% | 58.1% |
PIC
Overall survival63.3%
Survival free of stroke58.1%
Observational data: associations, not effects.
Further findings
| Outcome | PIC | Pump exchange | AC | |
|---|---|---|---|---|
| Survival free of stroke · 5 years | 58.1% | Not reported in the abstract | Not reported in the abstract | Pump exchange, AC: not reported in the abstract |
Functional capacity (6-min walk distance) · baseline and 5 years
- Baseline
- 104 ± 140 m
- 5 years (significant improvement, maintained)
- 301 ± 131 m
Quality of life (QoL) (EuroQoL-5 Dimensions-5 Levels visual analogue scale) · baseline and 5 years
- Baseline
- 35 ± 19 points
- 5 years (significant improvement, maintained)
- 64 ± 20 points
Original publication
Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry. Eur Heart J. Published 30 November 2023. doi:10.
Summarised from the published abstract; every number is checked against it